Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ScTIL and Toripalimab in Gynecological Malignancies
NCT05342506Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2022
- Primary completion
- Feb 2024
- Modality
- Cell Therapies
01
Overview
Phase 2, open-label trial of ScTIL in Cervical Cancer (CC), ovarian cancer and gestational trophoblastic neoplasia (GTN) (3 cohorts), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 12 weeks. Status: unknown.
02
Drugs
ScTIL
03
Conditions
Cervical Cancer (CC)ovarian cancergestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT05342506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05342506.